CD8A and cancer: It has recently been shown that combining glutamine antagonist and anti-PD-1 immunotherapy dramatically improves antitumor effects compared with anti-PD-1 therapy alone (69), revealing the bidirectional effect of glutamine deprivation with increasing OXPHOS and cell activity of CD8+ T cells and decreasing the glycolysis in cancer cells.